Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment
| Autor: | Albert Elion-Mboussa, Jed C. Kaminetsky, Lars Viktrup, Claus G. Roehrborn, Stephen Auerbach, Rafael Martínez Montelongo |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Male
medicine.medical_specialty medicine.drug_mechanism_of_action Phosphodiesterase Inhibitors Urology Urinary system media_common.quotation_subject Prostatic Hyperplasia Urination urologic and male genital diseases Placebo Tadalafil Erectile Dysfunction Lower urinary tract symptoms Statistical significance medicine Humans Aged media_common Dose-Response Relationship Drug business.industry Middle Aged medicine.disease Surgery Urodynamics Treatment Outcome Erectile dysfunction Epidemiologic Methods business Prostatism Phosphodiesterase 5 inhibitor Carbolines medicine.drug |
| Zdroj: | BJU International. 105:502-507 |
| ISSN: | 1464-410X 1464-4096 |
| DOI: | 10.1111/j.1464-410x.2009.08822.x |
| Popis: | Study Type – Therapy (RCT) Level of Evidence 1b OBJECTIVE To determine, by post hoc analysis, the effects of tadalafil (a long-acting phosphodiesterase 5 inhibitor) on peak urinary flow (Qmax), bladder capacity, voiding efficiency and the obstructive symptoms of benign prostatic hyperplasia (BPH) in men with lower urinary tract symptoms secondary to BPH (BPH-LUTS), compared with placebo. PATIENTS AND METHODS After a 4-week placebo run-in period, 1058 men with BPH-LUTS were randomly allocated to receive once daily treatment with placebo or tadalafil (2.5, 5, 10, or 20 mg) for 12 weeks. Uroflowmetry, postvoid residual volume (PVR), and BPH symptom score measurements were assessed throughout the trial. RESULTS Increases in Qmax were numerically greater for tadalafil (2.5, 5, 10, and 20 mg with percentage changes of 15%, 16%, 17%, 22%, respectively) vs placebo (12%), but did not reach statistical significance. Age, baseline Qmax, erectile dysfunction history, sexual activity, and previous α-blocker therapy significantly influenced the Qmax response. Tadalafil was not associated with significant changes in PVR. Tadalafil had its greatest effects on bladder capacity and voiding efficiency in men with a Qmax of |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|